These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 2971021)

  • 1. Activation of mononuclear cells to be used for hybrid monoclonal antibody-induced lysis of human ovarian carcinoma cells.
    Pupa SM; Canevari S; Fontanelli R; Ménard S; Mezzanzanica D; Lanzavecchia A; Colnaghi MI
    Int J Cancer; 1988 Sep; 42(3):455-9. PubMed ID: 2971021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human ovarian carcinoma lysis by cytotoxic T cells targeted by bispecific monoclonal antibodies: analysis of the antibody components.
    Mezzanzanica D; Canevari S; Ménard S; Pupa SM; Tagliabue E; Lanzavecchia A; Colnaghi MI
    Int J Cancer; 1988 Apr; 41(4):609-15. PubMed ID: 3258590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific-monoclonal-antibody-directed lysis of ovarian carcinoma cells by activated human T lymphocytes.
    Möller SA; Reisfeld RA
    Cancer Immunol Immunother; 1991; 33(4):210-6. PubMed ID: 1647871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
    Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
    Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re-targeting of human lymphocytes expressing the T-cell receptor gamma/delta to ovarian carcinoma cells by the use of bispecific monoclonal antibodies.
    Ferrini S; Prigione I; Mammoliti S; Colnaghi MI; Ménard S; Moretta A; Moretta L
    Int J Cancer; 1989 Aug; 44(2):245-50. PubMed ID: 2527207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.
    Itoh K; Platsoucas CD; Balch CM
    J Exp Med; 1988 Oct; 168(4):1419-41. PubMed ID: 3262710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19 (NKH1)-positive recombinant IL-2-activated cultures of lymphocytes infiltrating human ovarian tumors.
    Heo DS; Whiteside TL; Kanbour A; Herberman RB
    J Immunol; 1988 Jun; 140(11):4042-9. PubMed ID: 3286766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-ovarian carcinoma anti-T3 heteroconjugates or hybrid antibodies induce tumor cell lysis by cytotoxic T-cells.
    Canevari S; Ménard S; Mezzanzanica D; Miotti S; Pupa SM; Lanzavecchia A; Colnaghi MI
    Int J Cancer Suppl; 1988; 2():18-21. PubMed ID: 3258291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific antibody-directed antitumor activity of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus interleukin 2.
    Nishimura T; Nakamura Y; Takeuchi Y; Gao XH; Tokuda Y; Okumura K; Habu S
    Jpn J Cancer Res; 1991 Nov; 82(11):1207-10. PubMed ID: 1836455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ICAM- melanoma cells are relatively resistant to CD3-mediated T-cell lysis.
    Braakman E; Goedegebuure PS; Vreugdenhil RJ; Segal DM; Shaw S; Bolhuis RL
    Int J Cancer; 1990 Sep; 46(3):475-80. PubMed ID: 1975566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of culture conditions for activation and large-scale expansion of human T lymphocytes for bispecific antibody-directed cellular immunotherapy.
    Lamers CH; van de Griend RJ; Braakman E; Ronteltap CP; Bénard J; Stoter G; Gratama JW; Bolhuis RL
    Int J Cancer; 1992 Jul; 51(6):973-9. PubMed ID: 1386349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting human T-lymphocytes with bispecific antibodies to react against human ovarian carcinoma cells growing in nu/nu mice.
    Garrido MA; Valdayo MJ; Winkler DF; Titus JA; Hecht TT; Perez P; Segal DM; Wunderlich JR
    Cancer Res; 1990 Jul; 50(14):4227-32. PubMed ID: 2142014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anti-tumor effect of cytotoxic T lymphocytes induced by soluble antigen of ovarian carcinoma and anti-CD3 monoclonal antibody on ovarian carcinoma].
    Zhang Q; Wan Y; Zhai H
    Zhonghua Fu Chan Ke Za Zhi; 1998 Jun; 33(6):355-7. PubMed ID: 10806675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Membrane-bound anti-CD3 monoclonal antibodies trigger cytolytic T-lymphocyte-mediated tumor lysis.
    Mentzer SJ; Wilson RE; Burakoff SJ; Herrmann SH
    Arch Surg; 1988 Oct; 123(10):1280-5. PubMed ID: 3263103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficiency of T cell triggering by anti-CD3 monoclonal antibodies (mAb) with potential usefulness in bispecific mAb generation.
    Jacobs N; Mazzoni A; Mezzanzanica D; Negri DR; Valota O; Colnaghi MI; Moutschen MP; Boniver J; Canevari S
    Cancer Immunol Immunother; 1997 Jul; 44(5):257-64. PubMed ID: 9247560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced in vitro lysis of human ovarian carcinomas with activated peripheral blood lymphocytes and bifunctional immune heteroaggregates.
    Donohue JH; Ramsey PS; Kerr LA; Segal DM; McKean DJ
    Cancer Res; 1990 Oct; 50(20):6508-14. PubMed ID: 2145062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of the lytic activity of cloned human CD8 tumour-infiltrating lymphocytes by bispecific monoclonal antibodies.
    Gorter A; Krüse KM; Schrier PI; Fleuren GJ; van de Griend RJ
    Clin Exp Immunol; 1992 Jan; 87(1):111-6. PubMed ID: 1531120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
    Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased lysis of patient CD10-positive leukemic cells by T cells coated with anti-CD3 Fab' antibody cross-linked to anti-CD10 Fab' antibody.
    Oshimi K; Seto T; Oshimi Y; Masuda M; Okumura K; Mizoguchi H
    Blood; 1991 Mar; 77(5):1044-9. PubMed ID: 1825287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (alpha CD3/alpha CD19).
    Haagen IA; van de Griend R; Clark M; Geerars A; Bast B; de Gast B
    Clin Exp Immunol; 1992 Dec; 90(3):368-75. PubMed ID: 1281055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.